Diabetic complications in the cornea

被引:161
作者
Ljubimov, Alexander V. [1 ,2 ]
机构
[1] UCLA, Cedars Sinai Med Ctr, Board Governors Regenerat Med Inst, Dept Biomed Sci,Eye Program, 8700 Beverly Blvd,AHSP A-8319, Los Angeles, CA 90048 USA
[2] UCLA, David Geffen Sch Med UCLA, 8700 Beverly Blvd,AHSP A-8319, Los Angeles, CA 90048 USA
关键词
Diabetic cornea; Keratopathy; Neuropathy; Gene therapy; Naltrexone Insulin; Corneal epithelium; AGEs; Limbal stem cell; Dry eye; Growth factors; Proteinases; EPITHELIAL BASEMENT-MEMBRANE; GLYCATION END-PRODUCTS; OCULAR SURFACE CHANGES; GROWTH-FACTOR RECEPTOR; ALDOSE REDUCTASE INHIBITOR; IN-SITU KERATOMILEUSIS; CELL MARKER PATTERNS; NERVE-FIBER DAMAGE; MELLITUS TYPE-I; CONFOCAL MICROSCOPY;
D O I
10.1016/j.visres.2017.03.002
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Diabetic corneal alterations, such as delayed epithelial wound healing, edema, recurrent erosions, neuropathy/loss of sensitivity, and tear film changes are frequent but underdiagnosed complications of both type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus. The disease affects corneal epithelium, corneal nerves, tear film, and to a lesser extent, endothelium, and also conjunctiva. These abnormalities may appear or become exacerbated following trauma, as well as various surgeries including retinal, cataract or refractive. The focus of the review is on mechanisms of diabetic corneal abnormalities, available animal, tissue and organ culture models, and emerging treatments. Changes of basement membrane structure and wound healing rates, the role of various proteinases, advanced glycation end products (AGEs), abnormal growth and motility factors (including opioid, epidermal, and hepatocyte growth factors) are analyzed. Experimental therapeutics under development, including topical naltrexone, insulin, inhibitors of aldose reductase, and AGEs, as well as emerging gene and cell therapies are discussed in detail. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:138 / 152
页数:15
相关论文
共 247 条
[1]   New therapeutic approaches in the treatment of diabetic keratopathy: a review [J].
Abdelkader, Hamdy ;
Patel, Dipika V. ;
McGhee, Charles N. J. ;
Alany, Raid G. .
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2011, 39 (03) :259-270
[2]   Conjunctival Flora in Diabetic and Nondiabetic Individuals [J].
Adam, Mehmet ;
Balci, Mehmet ;
Bayhan, Hasan Ali ;
Inkaya, Ahmet Cagkan ;
Uyar, Mehmet ;
Gurdal, Canan .
TURK OFTALMOLOJI DERGISI-TURKISH JOURNAL OF OPHTHALMOLOGY, 2015, 45 (05) :193-196
[3]  
Aiello L., 1999, Curr Opinion Endocrinol and Diabetes, V6, P146
[4]   Diabetic retinopathy [J].
Aiello, LP ;
Gardner, TW ;
King, GL ;
Blankenship, G ;
Cavallerano, JD ;
Ferris, FL ;
Klein, R .
DIABETES CARE, 1998, 21 (01) :143-156
[5]   Growth factors and protein kinase C inhibitors as novel therapies for the medical management diabetic retinopathy [J].
Aiello, LP ;
Cahill, MT ;
Cavallerano, JD .
EYE, 2004, 18 (02) :117-125
[6]   Change in Long-Spacing Collagen in Descemet's Membrane of Diabetic Goto-Kakizaki Rats and Its Suppression by Antidiabetic Agents [J].
Akimoto, Yoshihiro ;
Sawada, Hajime ;
Ohara-Imaizumi, Mica ;
Nagamatsu, Shinya ;
Kawakami, Hayato .
EXPERIMENTAL DIABETES RESEARCH, 2008, :818341
[7]  
Alves MD, 2008, ARQ BRAS OFTALMOL, V71, P96, DOI 10.1590/S0004-27492008000700018
[8]   A review of therapies for diabetic macular oedema and rationale for combination therapy [J].
Amoaku, W. M. K. ;
Saker, S. ;
Stewart, E. A. .
EYE, 2015, 29 (09) :1115-1130
[9]  
AZAR DT, 1989, ACTA OPHTHALMOL, V67, P72
[10]   DECREASED PENETRATION OF ANCHORING FIBRILS INTO THE DIABETIC STROMA - A MORPHOMETRIC ANALYSIS [J].
AZAR, DT ;
SPURRMICHAUD, SJ ;
TISDALE, AS ;
GIPSON, IK .
ARCHIVES OF OPHTHALMOLOGY, 1989, 107 (10) :1520-1523